Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110 Apr 18, 2018
Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform Mar 26, 2018
Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards Mar 19, 2018
Heat Biologics to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium Mar 14, 2018
Heat Biologics to Present at the BIO-Europe Spring Conference, March 12-14, 2018, in Amsterdam Mar 13, 2018
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Feb 28, 2018
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study Feb 26, 2018
Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer Feb 20, 2018
